LBRX Key Statistics, Chart & Performance
The current stock price of LBRX is 16.32 USD. In the past month the price decreased by -3.35%.
LBRX Latest News, Press Relases and Analysis
LBRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.77 | 1.04T | ||
| JNJ | JOHNSON & JOHNSON | 19.93 | 498.19B | ||
| MRK | MERCK & CO. INC. | 11.82 | 260.02B | ||
| PFE | PFIZER INC | 8 | 145.49B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.45 | 99.53B | ||
| ZTS | ZOETIS INC | 20 | 56.20B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.64 | 23.11B | ||
| VTRS | VIATRIS INC | 4.54 | 12.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.36 | 11.62B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.23 | 8.35B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.52B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.48B |
Related stock screener links
About LBRX
Company Profile
LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company is headquartered in New York City, New York. The company went IPO on 2025-09-11. The firm is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The firm is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The firm is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
Company Info
LB PHARMACEUTICALS INC
One Pennsylvania Plaza, Suite 1025
New York City NEW YORK US
Employees: 0
Phone: 19174506581
LB PHARMACEUTICALS INC / LBRX FAQ
What does LBRX do?
LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company is headquartered in New York City, New York. The company went IPO on 2025-09-11. The firm is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The firm is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The firm is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
What is the stock price of LB PHARMACEUTICALS INC today?
The current stock price of LBRX is 16.32 USD. The price increased by 1.12% in the last trading session.
Does LBRX stock pay dividends?
LBRX does not pay a dividend.
How is the ChartMill rating for LB PHARMACEUTICALS INC?
LBRX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for LB PHARMACEUTICALS INC?
LB PHARMACEUTICALS INC (LBRX) currently has 0 employees.
What is LB PHARMACEUTICALS INC worth?
LB PHARMACEUTICALS INC (LBRX) has a market capitalization of 366.22M USD. This makes LBRX a Small Cap stock.
LBRX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to LBRX.
LBRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LBRX. While LBRX has a great health rating, there are worries on its profitability.
LBRX Financial Highlights
Over the last trailing twelve months LBRX reported a non-GAAP Earnings per Share(EPS) of -2.81. The EPS decreased by -905.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.67% | ||
| ROE | -20.34% | ||
| Debt/Equity | 0 |
LBRX Forecast & Estimates
9 analysts have analysed LBRX and the average price target is 47.26 USD. This implies a price increase of 189.58% is expected in the next year compared to the current price of 16.32.